We’re excited to be heading to Aspen Ideas: Health next week as a proud sponsor, joining policymakers, technology innovators and clinicians to tackle some of healthcare’s biggest challenges. This year’s theme, “Better Health for All” is what drives us at Dexcom and it’s what we’ll be exploring during our panel. On June 23, Dexcom President and CEO, Jake Leach, will join biochemist, bestselling author and Glucose Goddess Founder, Jessie Inchauspé for “Glucose Biosensing for All: Making Preventative Care the Standard of Care,” moderated by Ami Bhatt, MD, Chief Innovation Officer at the American College of Cardiology. Glucose impacts all of us. It’s influenced by what we eat, how well we sleep, even how stressed we feel – making it foundational to overall health. This conversation will explore how understanding and managing glucose can help shift care from reactive to preventative and what it will take to make biosensing technology more accessible to everyone. If you’re attending or covering the event, we’d love to see you. We’ll also share takeaways from the conversation next week. Learn more here: https://lnkd.in/geav9RdP

Today, Dexcom released results from the most significant clinical study demonstrating CGM benefits for people with Type 2 diabetes not using insulin. The CONNECT randomized control study, presented at the 2026 Scientific Sessions of the American Diabetes Association in New Orleans, demonstrated a clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin, compared with a routine care control group using self-monitoring of blood glucose.* 💬 “This is the third Dexcom-sponsored randomized controlled trial that has, or will, drive Dexcom CGM to be the standard of care in people with Type 2 diabetes. We anticipate these results will help establish a new standard of care in the U.S. and around the world.”  – Jake Leach, Dexcom President and CEO To learn more about Dexcom’s CONNECT study, including results, visit: https://lnkd.in/gv79uxH3 ### *Oser T, et al. CGM for Adults with Type 2 Diabetes Not on Insulin: The CONNECT Randomized Controlled Trial. Presented at the 2026 Scientific Sessions of the American Diabetes Association, June 6, 2026. New Orleans, LA; USA.

At #ADA2026, Dexcom is reinforcing a simple but powerful belief: Dexcom CGM technology can benefit all people with diabetes and looking ahead, can support early-stage intervention and preventive care. We’re excited to share several updates that reflect how we’re continuing to expand access, drive innovation and most importantly, increase our impact: • 𝐍𝐞𝐰 𝐜𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐞𝐯𝐢𝐝𝐞𝐧𝐜𝐞: Results from the CONNECT randomized controlled trial will highlight the benefits of Dexcom CGM for adults with Type 2 diabetes not using insulin therapy. This study, which will be presented on Saturday, June 6 at 1:45 p.m CDT, has the potential to influence future standards of care. More to come! • 𝐑𝐞𝐢𝐦𝐚𝐠𝐢𝐧𝐞𝐝 𝐒𝐭𝐞𝐥𝐨 𝐞𝐱𝐩𝐞𝐫𝐢𝐞𝐧𝐜𝐞: A completely redesigned app experience rolling out later this summer will introduce a suite of new features including pattern recognition, proactive AI coaching and personalized daily and weekly summaries. • 𝐍𝐮𝐭𝐫𝐢𝐬𝐞𝐧𝐬𝐞 𝐚𝐜𝐪𝐮𝐢𝐬𝐢𝐭𝐢𝐨𝐧 𝐚𝐠𝐫𝐞𝐞𝐦𝐞𝐧𝐭: By entering into an agreement to acquire Nutrisense, this acquisition will enhance Dexcom’s nutrition capabilities by strengthening our ability to provide personal nutrition education and guidance linking food choices to glucose responses. Together, these announcements demonstrate how Dexcom continues to lead and push the boundaries of what’s possible in diabetes care and metabolic health. 🔗 𝐋𝐞𝐚𝐫𝐧 𝐦𝐨𝐫𝐞 𝐚𝐛𝐨𝐮𝐭 𝐨𝐮𝐫 𝐀𝐃𝐀 𝐮𝐩𝐝𝐚𝐭𝐞𝐬 𝐡𝐞𝐫𝐞: https://lnkd.in/g5rmq-zC. #Dexcom #ADA2026 #CGM

Dexcom has been selected by the U.S. Food and Drug Administration (FDA) as the first company to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. Glucose is one of the body’s most powerful health signals. Participating in the TEMPO pilot program will enable Dexcom to implement a glucose health program that will deliver more personalized insights for healthcare professionals and users, while also aiding in screening for prediabetes and Type 2 diabetes. Dexcom is proud to drive innovation at the intersection of digital and glucose health, empowering people to take control of health.  Learn more here. https://lnkd.in/g8cb_BQg

We’re excited to be in Barcelona for the 19th annual Advanced Technologies & Treatments for Diabetes (ATTD) showcasing how Dexcom’s latest findings and innovations are transforming care for people with all types of diabetes. Highlights from the week include: • New registry study data shows that long-term use of Dexcom G7 supports weight management and lowers A1C for people with Type 2 diabetes who aren’t on insulin therapy, reinforcing the need to broaden CGM access beyond insulin-treated populations. • New evidence shows how Dexcom CGM can help improve long-term health and reduce hospitalizations across diabetes types. • Symposium on Thursday, March 12, led by Girish Naganathan, will highlight upcoming product features across Dexcom’s global portfolio. Every year, ATTD continues to push diabetes care forward. We’re proud of the role we play in shaping the future of glucose biosensing and advancing metabolic health worldwide. For more information about Dexcom's presence at ATTD, read the news release here https://lnkd.in/1wf642v4. And to register to virtually attend the conference, visit https://lnkd.in/64h0yrrm. #ATTD2026 #Dexcom #GlucoseBiosensing #DiabetesCare #CGM

Continuing to transform how people manage their glucose, Dexcom is proud to announce new features coming to Stelo, the first over-the-counter glucose biosensor cleared* by the FDA in the United States. 𝗔𝗱𝘃𝗮𝗻𝗰𝗲𝗱 𝗔𝗜-𝗲𝗻𝗮𝗯𝗹𝗲𝗱 𝗦𝗺𝗮𝗿𝘁 𝗙𝗼𝗼𝗱 𝗟𝗼𝗴𝗴𝗶𝗻𝗴: • Expansion of previously launched Smart Food Logging feature • Integrates a comprehensive nutrition database that provides a breakdown of calories, carbohydrates, protein, fat, dietary fibers, and more • Includes over 1M food options • Multiple ways to log a meal, including text search, barcode scanning or taking a photo of the meal 𝗥𝗲𝗱𝗲𝘀𝗶𝗴𝗻𝗲𝗱 𝗗𝗮𝗶𝗹𝘆 𝗜𝗻𝘀𝗶𝗴𝗵𝘁𝘀: • New interface with a sophisticated, card-based system • Users will receive up to three personalized recommendations based on their previous day's glucose, activity, nutrition, and sleep data • Personalized coaching that adapts to individual patterns and progress    These features, launching nationwide in the coming weeks, will empower users with even more information to better understand and manage their metabolic health. Read more here: https://lnkd.in/gkGyFBUK *Dexcom, Stelo User Guide, 2024.

Dexcom has teamed up with DAV (Disabled American Veterans) to launch a new diabetes resource page created just for veterans. With diabetes impacting nearly 1 in 4 veterans, this page is designed to help veterans feel empowered and supported in managing their health. Thank you to the team at DAV for being great partners. We are proud of the work we’re doing together to support those who have served.

The science and innovation on display at #ADA2026 continue to shape the future of standards of care. Dexcom’s CONNECT study is a powerful example, demonstrating clinically significant benefits for adults with Type 2 not using insulin. As the reach of glucose biosensing technology expands, its impact continues to grow, helping transform health at scale.